PRESS RELEASES

Sunovion and PsychoGenics Initiate DIAMOND Phase 3 Clinical Studies for SEP-363856 in the Treatment of Adults and Adolescents with Schizophrenia

September 27, 2019

PUBLICATION

Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington’s disease

July 9, 2019

PRESS RELEASES

Sunovion and PsychoGenics Announce that SEP-363856 Has Received FDA Breakthrough Therapy Designation for the Treatment of People with Schizophrenia

May 10, 2019

PUBLICATION

Validated Phenotypic Approach to Neuropsychiatric Drug Discovery

March 1, 2019

PUBLICATION

Biomarker Analysis of Orally Dosed, Dual Active, Matrix Metalloproteinase (MMP)-2 and MMP-9 Inhibitor, AQU-118, in the Spinal Nerve Ligation (SNL) Rat Model of Neuropathic Pain

February 1, 2019

PUBLICATION

Myelinated axons fail to develop properly in a genetically authentic mouse model of Charcot-Marie-Tooth disease type 2E

October 1, 2018

PUBLICATION

Differences in Synaptic Dysfunction Between rTg4510 and APP/PS1 Mouse Models of Alzheimer’s Disease

August 1, 2018

PUBLICATION

Synergistic antileukemic therapies in NOTCH1-induced T-ALL.

October 12, 2017

PUBLICATION

Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response

October 11, 2017